Clinical Trial Update: Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial is exploring partial immune-boosted TACE for unresectable hepatocellular carcinoma in patients receiving systemic treatment. The study status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: HCC, Tace | Phase 2 | Status: NOT_YET_RECRUITING